home > > winter 2020 > the elephant in the room

The Elephant in the Room

Attracting a healthy flow of studies is a pain point for many clinical research sites. Without a reliable pipeline of suitable leads, a research business will flounder. However, the fact is, while other industries frequently employ dedicated business development (BD) specialists to ensure ongoing revenue, the average investigative site does not. Rather, BD is often conducted by research staff with neither the training nor the time to be effective in building the solid foundation required for a successful research site.

Planning Is Key

To be successful, an investigative site must be managed as strategically as any other business, so it is useful to start with a few basic questions: how much growth do I want to see in this business over the next one, three, or five years? How much business is required to make the effort worthwhile and ensure a profitable return on investment? What do I need to do to achieve my goals?

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Kurt Mussina brings more than 30 years of international business success to his role at Frenova Renal Research, including a record of leadership and achievement in structuring and orchestrating global BD teams in the contract research services industry. As President, he is responsible for driving Frenova’s global growth and success.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations. Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.
More info >>

White Papers

Accelerate Your Database Lock Using Clean Patient Optics


Because a key step towards database lock is obtaining clean data for all patients, the ability to verify that data are clean early accelerates the ability to lock the clinical database. This ultimately shortens the overall study timeline while ensuring the quality of your data. However, this can be challenging when manually reviewing study data, particularly with larger studies.
More info >>

Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement